Trial Condition(s):

Prostatic Neoplasms, Castration-Resistant

A local retrospective observational study to evaluate the treatment patterns of mCRPC patients in Belgium treated with Radium-223 (BELFIGO)

Bayer Identifier:

20239

ClinicalTrials.gov Identifier:

NCT03563014

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The aim of this non interventional study is to describe the proportion of Belgian mCRPC patients which were treated with 1 to 4 and 5 to 6 Radium-223 injections and the patient characteristics which are potentially associated with this proportion.

Inclusion Criteria
-	Patients with a diagnosis of castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases
-	All consecutive patients who started Radium-223 treatment between 22 December 2014 and 01 June 2017
-	Availability of medical records during the observation period (22DEC2013 – 01JUN2018)
Exclusion Criteria
-	Patients treated with Radium-223 for any reason before 22 December 2014 (for example an interventional trial)
-	Patients participated in an investigational program with interventions outside of routine clinical practice during the radium-223 treatment period
-	Patients received other radiopharmaceuticals for the systemic concomitant use for treatment of prostate cancer or for other use during the Radium-223 treatment period

Trial Summary

Enrollment Goal
164
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Xofigo (Radium-223 dichloride, BAY88-8223)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Many Locations

Many Locations, Belgium

Status
Completed
 

Trial Design